Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo
S. Talon et al., Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo, BR J PHARM, 134(7), 2001, pp. 1523-1531
1 Searching for the structural requirements improving the potency and the s
tereoselectivity of Na+ channel blockers as antimyotonic agents, new deriva
tives of tocainide, in which the chiral carbon atom is constrained in a rig
id alpha -proline or pyrrolo-imidazolic cycle, were synthesized as pure ena
ntiomers.
2 Their ability to block Na+ currents, elicited from -100 to -20 mV at 0.3
Hz (tonic block) and 2-10 Hz (use-dependent block) frequencies, was investi
gated in vitro on single fibres of frog semitendinosus muscle using the vas
eline-gap voltage-clamp method.
3 The alpha -proline derivative, To5, was 5 and 21 fold more potent than to
cainide in producing tonic and 10 Hz-use-dependent block, respectively. Com
pared to To5, the presence of one methyl group on the aminic (To6) or amidi
c (To7) nitrogen atom decreased use-dependence by 2- and 6-times, respectiv
ely. When methylene moieties were present on both nitrogen atoms (To8), bot
h tonic and use-dependent block were reduced.
4 Contrarily to tocainide, all proline derivatives were stereoselective in
relation to an increased rigidity. A further increase in the molecular rigi
dity as in pyrrolo-imidazolic derivatives markedly decreased the drug poten
cy with respect to tocainide.
5 Antimyotonic activity, evaluated as the shortening of the time of rightin
g reflexes of myotonic adr/adr mice upon acute drug in vivo administration
was 3 fold more effective for R-To5 than for R-Tocainide.
6 Thus, constraining the chiral centre of tocainide in alpha -proline cycle
leads to more potent and stereoselective use-dependent Na+ channel blocker
s with improved therapeutic potential.